Notch Takes Steps to Preserve Cash and Explore Alternative Paths Forward

The biotech market has faced significant challenges over the last few years, with early-stage cell therapy companies being significantly affected. Unfortunately, Notch is not immune from this environment. While we have made considerable progress, securing additional investment and/or additional partners to take our research forward remains challenging. We have made the difficult decision to significantly reduce our workforce to preserve cash and provide the time to explore alternate paths forward.

Our talented people have been the backbone in all we’ve accomplished as we worked to advance iPSC-based T-cell therapy since 2018. We deeply appreciate each person’s contributions and are supporting our team though this difficult transition.

We are grateful for all the support Notch has received over the years and we are hopeful our contributions to the cell therapy field will continue to be realized.